Company Background


The Acute Myeloid Leukemia (AML) research group at Haukeland University Hospital started to use CMV for analysis of in-house sequencing data and provided positive feedback on functionality and data quality. Established collaboration agreement.

Since 2018, we have used CMV in more than 40 patient cases providing evidence of both the uniqueness and excellence of the personalised advice on their disease, as well as the willingness to pay.


Developed a prototype of the Coremine Vitae for providing qualified medical information relevant for the patient-specific tumour profile:

Provides information about most recent developments related to their own disease, including global treatment alternatives based on their individual medical profile, included biomarkers.

Provides information about local and international treatment guidelines, clinical trials, biomarker status and research.

Utilises technologies as text-mining, statistical analysis, knowledge-based data integration and machine learning, and consists of the cancer knowledge base, data analysis and interpretation algorithm for annotation, ranking, and predicting important mutations responsible for tumour development and a clinical trial monitoring and matching module, which automatically scans clinical trial databases and finds applicable trials for patients.


Launched CORMINE Oncology; a tool for analysing complex cancer-specific mutational profiles (extracted from patient biopsies using next generation sequencing) and leveraging many features of the COREMINE Platform and COREMINE Medical. The tool guides the oncologist through the mutational maze, identifying key drivable and druggable mutations, and also helps the oncologist to select the optimal treatment regimen (or clinical trial).

Iterative development of the tumour variant data interpretation software using a set of de-identified mutation profiles (SNV, CNV and gene expression).

Developed software module for clinical trials mining, and compiled a database containing the associations between clinical trials and biomarkers, cancer type, drugs, countries, etc.

Added 2-factor authentication mechanism to enhance data security (incl.
hardware protection & user authorization).


Identified biomedical data sources and which part of information are useful, how to parse/extract the relevant information in order to calculate relationship between different medical concepts.

Compiled a prototype of a proprietary cancer knowledge base on the analysis of multiple qualified scientific and biomedical data sources.

Laid foundation for automatic and semi- automatic data update protocols and tools.

Extended COREMINE Medical with the new cancer knowledge base.


Launched COREMINE Medical, a domain-specific information community built on top of the COREMINE Platform. COREMINE Medical is an Internet service for searching, updating, and sharing medical information. The service is targeted at medical health professionals, researchers and scientists and medical information about diseases, treatments, drugs, etc. COREMINE Medical enables biomedical researchers to navigate complex information networks and qualify associations that can stimulate new insights and help improve the users understanding of complex biological systems.


In 2005, PubGene Inc. acquired Sencel Bioinformatics AS, and the PubGene Group comprises PubGene AS, Sencel Bioinformatics AS, and PubGene Inc.By the end of 2005, the PubGene strategy was further refined to develop the technology and deploy the resources broader for implementation of the COREMINE platform for domain-specific search engines. This included also community features enabling the user to make updates in the context networks and exchanging networks of information with other users. In parallel, the development of COREMINE Medical was started based on the COREMINE Platform. The service was launched September 2011.


In 2004, the PubGene product was further extended with new features and data generated from additional data sources. PubGene signed license contracts with leading enterprises, such as Pfizer, Johnson & Johnson, Beckman Coulter, Mayo Clinic, and the Karolinska Hospital.


2002- In 2002, PubGene filed a US patent that was approved in 2007, covering the search concept and core technology.


2001- PubGene Inc. was established in August 2001 in Boston, MA, by researchers at the Norwegian University of Science and Technology, and the Norwegian Radium Hospital. A subsidiary, PubGene AS, was established at the same time in Norway. In 2001 aswell, PubGene signed an agreement with the US National Institute of Health’s PubMed (MEDLINE) for extracting information from the PubMed database. PubGene received a lot of positive attention after publishing in Nature Genetics (2001/28) and Pharmacogenomics Journal (2001/1), and different interviews, e.g., in The Economist, The Wall Street Journal, and Reuters


1998- The initial development dates back to 1998 based on access to MEDLINE and human gene name databases.